Natera (NTRA) Stock Price, News & Analysis

+0.46 (+0.51%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
847,287 shs
Average Volume
1.21 million shs
Market Capitalization
$11.05 billion
P/E Ratio
Dividend Yield
Price Target

Natera MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
5.6% Downside
$86.40 Price Target
Short Interest
5.18% of Shares Sold Short
Dividend Strength
News Sentiment
0.27mentions of Natera in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$36.59 M Sold Last Quarter
Proj. Earnings Growth
From ($2.35) to ($1.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

704th out of 907 stocks

Medical Laboratories Industry

17th out of 20 stocks

NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Natera (NTRA) Rose on Momentum in the Oncology Market
Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Natera (NASDAQ:NTRA) Lowered to Sell at
Natera CEO sells shares worth over $630k
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share


Free Float
Market Cap
$11.05 billion
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

14 Wall Street analysts have issued 1 year price objectives for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they predict the company's share price to reach $86.40 in the next twelve months. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA stock has increased by 46.1% and is now trading at $91.50.
View the best growth stocks for 2024 here

Are investors shorting Natera?

Natera saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 6,250,000 shares, a decrease of 21.4% from the March 15th total of 7,950,000 shares. Based on an average trading volume of 1,520,000 shares, the short-interest ratio is presently 4.1 days.
View Natera's Short Interest

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.09. The medical research company earned $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.71%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Artemis Investment Management LLP (0.19%), Assenagon Asset Management S.A. (0.08%), Raymond James Financial Services Advisors Inc. (0.02%) and Maryland State Retirement & Pension System (0.01%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 4/25/2024 by Staff

From Our Partners